Study of IBI363 for extensive-stage small cell lung cancer after immunotherapy
Part of Cancer clinical trials.
This trial tests a new drug, IBI363, for people with extensive-stage small cell lung cancer whose cancer has not responded to 2 or 3 previous treatments, including immunotherapy. The goal is to see if IBI363 can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have extensive-stage small cell lung cancer that has progressed after 2 to 3 prior treatments, including immunotherapy.
- You have at least one measurable tumor that has not been previously irradiated or has shown clear growth after local therapy.
- You are physically active (ECOG performance status 0 or 1) and expected to live at least 3 months.
- Your organs are functioning well enough, and you do not have uncontrolled infections or other serious medical conditions.
- If you are fertile, you agree to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus standard chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination can be more effective than current treatments.
This trial tests a new drug called IBI363 for people with advanced solid tumors, focusing on lung cancer and melanoma. It aims to see if the drug is safe and effective, especially for those whose previous treatments have stopped working.
This trial tests a new drug called IBI363 for people with advanced cancer that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow cancer growth.
This trial tests a new drug called IBI363 for people with advanced solid tumors. It aims to see if the drug is safe and effective. You may be able to join if you are generally well and have not had other cancer treatments recently.
This trial tests a new drug called IBI3009 for people with advanced small cell lung cancer that cannot be removed by surgery. It aims to see how safe the drug is and how well it works against the cancer.
This trial tests a new drug combination—BL-B01D1 plus a PD-1 immunotherapy—for people who have just been diagnosed with extensive-stage small cell lung cancer and have not had any prior treatment for it. The goal is to see if this combination can help shrink or control the cancer better than standard therapy.
Hear when a new SCLC,Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.